Skip to main content
SpringerLink
Log in

Nevirapine useful in combination HIV therapy

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Firshein J. Accelerated approval of nevirapine. Lancet 1996 Jun 22; 347: 1755

    Article  Google Scholar 

  2. Patel SS, Benfield P. Nevirapine. Clin Immunother 1996 Oct; 6(4) 307–17

    Article  Google Scholar 

  3. HIV protease inhibitors: an important advance. Drug Ther Perspect 1996 Nov 11; 8(10): 1–6

    Article  Google Scholar 

  4. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990 Dec; 250(4986): 1411–3

    Article  PubMed  CAS  Google Scholar 

  5. Balzarini J, Karlsson A, Pérez-Pérez M-J, et al. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 1993 Oct; 196: 576–85

    Article  PubMed  CAS  Google Scholar 

  6. Mueller BU, Sei S, Luzuriaga K, et al. The impact of combination therapy (zidovudine + didanosine + nevirapine) on HIV-1 virus burden in peripheral blood and lymph node tissue in children [abstract]. J Invest Med 1995 Apr; 43 (2) Suppl. 2: 249A

    Google Scholar 

  7. Tomino C, Fragola V, Bucciardini R, et al. Tolerability of AZT+DDI and AZT+DDI+nevirapine among antiretroviral-naive patients with advanced HIV infection (AIDS or CD4+ <200/mm3): preliminary results [abstract no. B.2119]. Proceedings of the 11th International Conference on AIDS; 1996 Jul 7–12; Vancouver, Canada, 285

  8. De Jong M. Antiviral response to nevirapine monotherapy in nucleoside naive persons [abstract no. PB0847]. Proceedings of the 10th International Conference on AIDS; 1994 Aug 7–12; Yokohama, Japan, 208.

  9. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995 Mar; 171: 537–45

    Article  PubMed  CAS  Google Scholar 

  10. Carr A, Vella S, De Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996; 10: 635–41

    Article  PubMed  CAS  Google Scholar 

  11. Paar D, Pollard R, Hall D, et al. Nevirapine (NVP) in combination with zidovudine (ZDV) vs ZDV in nucleoside experienced patients [abstract no. 383]. Clin Infect Dis 1995 Sep; 21(3): 783

    Google Scholar 

  12. Loewenthal M, Hall D, de Jong MD, et al. Treatment with nevirapine and zidovudine in antiretroviral naive HIV-1 infected patients [abstract no. PO-B26-2101]. Proceedings of the 9th International Conference on AIDS; 1993 Jun 6–11; Berlin, Germany, 485

  13. D’Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996 Jun; 124(12): 1019–30

    PubMed  Google Scholar 

  14. Saag M, Johnson V, Wei X, et al. Clinical, pharmacokinetic, and virologic results in adults treated with nevirapine (Nev) in combination with AZT/ddC, AZT/ddl, or ddI alone: final report of the BI1009 study [abstract no. M16]. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7; Orlando, Florida, 218.

  15. Grob PM, Wu JC, Cohen KA, et al. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res Hum Retroviruses 1992 Feb; 8(2): 145–52

    Article  PubMed  CAS  Google Scholar 

  16. Weinberg RS, Chusid ED, Galperin Y, et al. Nevirapine (Nev) is less toxic to progenitor cells (BFU-E) than AZT or ddI [abstract no. PB0813]. Proceedings of the 10th International Conference on AIDS; 1994 Aug 7–12; Yokohama, Japan, 200.

  17. FDA approves nevirapine to treat HIV. FDA, http://www.fda.gov1996 Jun 24

  18. Warning on nevirapine interactions. Scrip 1996 Oct 18; 2173: 20

    Google Scholar 

  19. Havlir D. Nevirapine: a viewpoint by Diane Havlir. Clin Immunother 1996 Oct; 6(4) 318

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nevirapine useful in combination HIV therapy. Drugs Ther. Perspect 9, 1–5 (1997). https://doi.org/10.2165/00042310-199709040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199709040-00001

Search

Navigation